Current Opinion In Immunology

Journal Title：Current Opinion In Immunology

Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed.

In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications.

Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students.

Current Opinion in Immunology builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.

《免疫学最新观点》旨在促进基于科学、跨学科、多尺度的辩论和思想交流。它包含精炼、简洁和及时的评论和观点，特别强调过去两年发表的文章。除了描述最新趋势外，还鼓励作者对所讨论的主题发表主观意见。

在《免疫学最新观点》中，我们通过系统的方式帮助读者：1. 专家对其领域当前进展的看法，形式清晰易读。2. 对大量原始出版物中最有趣的论文进行评估，并由专家注释。

《免疫学最新观点》将成为研究人员、讲师、教师、专业人士、政策制定者和学生的宝贵信息来源。

《免疫学最新观点》以爱思唯尔在科学出版方面的卓越声誉和长期致力于传播旨在改善人类健康的可重复生物医学研究为基础。它是新黄金开放获取期刊《免疫学研究》的姊妹刊，也是《当前观点与研究》（CO+RE）期刊系列的一部分。所有 CO+RE 期刊都利用《当前观点》的传统——编辑卓越、影响力大、全球影响力——确保它们成为广泛阅读的资源，是科学家工作流程不可或缺的一部分。

Current Opinion In Immunology创刊于1988年，由Elsevier Ltd出版商出版，收稿方向涵盖医学 - 免疫学全领域，此刊是该细分领域中属于非常不错的SCI期刊，在行业细分领域中学术影响力较大，专业度认可很高，所以对原创文章要求创新性较高，如果您的文章质量很高，可以尝试。平均审稿速度 较慢,6-12周 ，影响因子指数6.6，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。